A carregar...
Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer
High-grade serous ovarian cancer (HGSOC) is the predominant and most lethal histological type of epithelial ovarian cancer. During the last few years, several new treatment options with PARP inhibitors have emerged. The FDA has approved the PARP inhibitor olaparib (Lynparza™) as maintenance treatmen...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6916751/ https://ncbi.nlm.nih.gov/pubmed/31857852 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27363 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|